IGC Pharma (IGC) Non-Current Assets (2011 - 2026)

IGC Pharma (IGC) has reported Non-Current Assets for 16 consecutive years, with $8.0 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Non-Current Assets rose 37.38% year-over-year to $8.0 million in Q1 2026; TTM through Mar 2026 was $8.0 million, a 37.38% increase from a year earlier, with the FY2026 full-year figure at $8.0 million, up 37.38% from the prior year.
• Non-Current Assets was $8.0 million for Q1 2026 at IGC Pharma, up from $7.9 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $11.7 million in Q1 2022 and troughed at $5.8 million in Q2 2025.
• A 5-year average of $8.5 million and a median of $7.9 million in 2025 frame the typical range for Non-Current Assets.
• Across the five-year window, Non-Current Assets tumbled 42.15% in 2024 and jumped 37.38% in 2026, its largest moves.
• Over 5 years, Non-Current Assets stood at $10.7 million in 2022, then retreated by 28.37% to $7.7 million in 2023, then decreased by 21.48% to $6.0 million in 2024, then surged by 31.44% to $7.9 million in 2025, then increased by 1.46% to $8.0 million in 2026.
• The last three Non-Current Assets figures came in at $8.0 million (Q1 2026), $7.9 million (Q4 2025), and $7.7 million (Q3 2025), per Business Quant data.